 |
| Home > Investors relations > Financials > Highlights |
|
| Highlights |
|
|
 The major scientific partnership agreement signed
with Eli Lilly & Company continued through 2006 and was recently renewed for 2007.
Most significant Cerep service agreements
were renewed for 2007.
During the second half of 2006, Hesperion acquired
TouchStone Research Inc., an American CRO. The acquisition of USD 3 million was made in cash and financed by
Hesperion. The purchase agreement provides for additional cash payments to be made upon achievement of
certain pre-established milestones. Such payments should not exceed a total of USD 2 million, mainly payable during 2007.
In January 2007, Cerep signed an agreement with
LS Pharma, Inc.*, USA, which allows LS Pharma to use the BioPrint® database developed by Cerep,
in order to reorient certain drugs. LS Pharma is an international drug development company founded
and managed by Mark Crawford and Vincent Charlon, who, until 2006, held senior management positions
within the Cerep Group.
In the last quarter of 2006, Cerep announced recent
achievements obtained in the Group’s oncology program. The results confirm the clinical effect of CER 227185;
Cerep also commented major progress achieved in 2006 in the development of CER233790 and new
promoters of tumor reversion.
At the end of 2006, Cerep announced its focusing
on profitable service activities of the Group.
* LS Pharma is an international drug development company founded by Mark Crawford, PhD,
a former President of Cerep, Inc. in the US, and by Vincent Charlon, PhD, a former CEO of the Swiss
clinical development company Hesperion, Ltd., a subsidiary of Cerep SA. LS Pharma uses information
in BioPrint®, a database developed by Cerep, to build a portfolio of drugs to be reoriented into new
indications, according to strict and pre established criteria. LS Pharma selects exclusively high
market potentials and low risk development and currently prepares the launching of its first clinical
studies for two of its most advanced projects.
|
|
|
|
|
 |
|
